GlassScriptPhysician profile
Natasha I Rowel
NPI 1740952324
$4,285.51
in general payments reported to CMS, 2019-2025
24 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $649 · 2023: $1,241 · 2024: $1,564 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.28 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $428.64 | 2023-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $350.55 | 2022-2024 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.62 | 2021-2024 | Xifaxan |
| Axonics, INC. | $321.12 | 2023-2024 | Axonics, Bulkamid |
| Lilly USA, LLC | $307.32 | 2023-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.10 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $290.10 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $225.87 | 2023-2024 | Korlym |
| Abbvie INC. | $225.25 | 2024 | |
| Medtronic, INC. | $188.22 | 2021-2023 | Interstim, Harmony |
| Dexcom, INC. | $125.56 | 2023 | Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| Abbott Laboratories | $124.98 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $120.12 | 2024 | Arexvy |
| Shield Therapeutics INC | $119.96 | 2023 | Accrufer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $118.68 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $113.06 | 2021 | |
| Krystal Biotech INC | $110.43 | 2024 | Vyjuvek |
| Hologic Sales and Service, LLC | $88.55 | 2025 | Aptima |
| Novo Nordisk INC | $85.93 | 2022 | |
| Paratek Pharmaceuticals, INC. | $83.33 | 2022 | |
| Ibsa Pharma INC. | $49.75 | 2023 | Licart |
| Aspira Women'S Health INC | $18.65 | 2022 | |
| Boston Scientific Corporation | $13.73 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Rowel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.